MetaCap

FibroBiologics (FBLG) vs GT Biopharma (GTBP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

FibroBiologics is the larger company by market cap ($6.3 million vs $6.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FBLG-38.16%GTBP-52.26%
+22%-17%-56%
Oct 7, 20261 yearNov 20, 2026
FBLG-37.61%GTBP-55.69%
+8%-25%-59%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FBLG versus GTBP key metrics
MetricFBLGGTBP
Share price$0.705$2.96
Market cap$6.34M$6.33M
1-day change-15.06%-6.92%
YTD return—+277.07%
1-year return—+303.27%
5-year return—-97.77%
EPS (TTM)$-2.51$-128.61
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-18.65M$-28.35M
52-week high$9.60$23.60
52-week low$0.62$2.87
Distance from 52-week high-92.66%-87.46%
Analyst consensusnonenone
Avg. price target upside+1673.05%+2433.78%
Average volume160.05K78.16K
Shares outstanding8.99M2.14M
Employees151
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About FibroBiologics

FBLG stock →

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

About GT Biopharma

GTBP stock →

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees

FBLG vs GTBP FAQ

Which is bigger, FibroBiologics or GT Biopharma?

FibroBiologics (FBLG) is larger, with a market capitalization of $6.34M compared with $6.33M for GT Biopharma (GTBP).

Are FibroBiologics and GT Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons